Risk of Stroke in Patients with Multiple Sclerosis Treated with Subcutaneous Interferon beta-1a (scIFNβ-1a)

被引：0
|
作者：
Sabido, Meritxell [1 ]
Venkatesh, Saritha [2 ]
Aldridge, Julie [2 ]
Gillett, Alan [3 ]
机构：
[1] Merck KGaA, Darmstadt, Germany
[2] EMD Serono Inc, Billerica, MA USA
[3] EMD Serono Inc, Mississauga, ON, Canada
来源：
NEUROLOGY | 2018年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S36.008
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Risk of stroke in patients with multiple sclerosis treated with subcutaneous interferon beta-1a
    Sabido-Espin, M.
    Venkatesh, S.
    Aldridge, J.
    Gillett, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 1022 - 1022
  • [2] Evaluation of the risk of malignancies in patients with multiple sclerosis treated with subcutaneous interferon beta-1a
    Alteri, E.
    Kornmann, G.
    Moraga, M. Stam
    Casset-Semanaz, F.
    Miret, M.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S204 - S205
  • [3] Evaluation of the risk of malignancy in patients with multiple sclerosis treated with subcutaneous interferon β-1a
    Sandberg-Wollheim, M.
    Kornmann, G.
    Moraga, M.
    Miret, M.
    Alteri, E.
    [J]. JOURNAL OF NEUROLOGY, 2010, 257 : S10 - S10
  • [4] Assessing the Risk of Malignancy in Patients with Multiple Sclerosis Receiving Subcutaneous Interferon beta-1a
    Sandberg-Wollheim, Magnhild
    Kornmann, Gabrielle
    Moraga, Margaretha Stam
    Miret, Montserrat
    Alteri, Enrica
    [J]. NEUROLOGY, 2010, 74 (09) : A61 - A62
  • [5] Evolution of New Lesions and its Temporal Patterns in Patients with Clinically Isolated Syndrome (CIS) Treated with Subcutaneous Interferon beta-1a (scIFNβ-1a)
    Vrenken, Hugo
    de Vos, Marlieke
    Battaglini, Marco
    Nagtegaal, Gijs J.
    de Almeida Teixeira, Bernardo Correa
    Marhardt, Kurt
    de Stefano, Nicola
    Barkhof, Frederik
    [J]. NEUROLOGY, 2018, 90
  • [6] Cost-effectiveness of 44 mcg subcutaneous interferon beta-1a (scIFNβ1a) and 30 mcg intramuscular interferon beta-1a (imIFNβ1a) using clinical endpoints of disease activity
    Phillips, A. L.
    Edwards, N. C.
    Locklear, J. C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 421 - 421
  • [7] Subcutaneous Interferon beta-1a Treatment and Pregnancy Outcomes in Patients with Multiple Sclerosis
    Sandberg-Wollheim, Magnhild
    Alteri, Enrica
    Moraga, Margaretha Stam
    Kornmann, Gabrielle
    [J]. NEUROLOGY, 2010, 74 (09) : A404 - A404
  • [8] Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis
    Freedman, Mark S.
    Jack, Dominic
    Murgasova, Zuzana
    Todorovic, Milorad
    Seitzinger, Andrea
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 56
  • [9] AUtoimmunity PRofile in INterferon beta-1a treated multiple sclerosis patients. The AUPRIN Study: Comparison of 2 different dosages of subcutaneous interferon beta-1a
    Verdun, E
    Giordano, L
    Cucci, MA
    Ricci, A
    Barbero, P
    Pipieri, A
    Clerico, M
    Aimo, G
    Durelli, L
    [J]. NEUROLOGY, 2005, 64 (06) : A384 - A385
  • [10] COMPARISON OF MEDICATION ADHERENCE TO INTERFERON BETA-1B AND INTERFERON BETA-1A SUBCUTANEOUS IN MULTIPLE SCLEROSIS PATIENTS
    Meletiche, D. M.
    Kozma, C.
    Dickson, M.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A194 - A194
12345